[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553927":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":27,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":10,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"HER2 low-expressing",null,[12],"Drug: Against HER 2-ADC Drug",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Against HER 2-ADC Drug","Breast cancer subjects receiving anti-HER2-ADC drugs were treated with a 3-week treatment cycle lasting 6 cycles. Serum of patients before and after treatment was collected, and the changes of serum HER2 level before chemotherapy and after 2, 4 and 6 cycles of chemotherapy were dynamically monitored, and the relationship between HER2 level and the therapeutic effect of different targeted drugs was analyzed.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Yehui Shi, PhD","CONTACT","+8618622221183","shiyehui@tjmuch.com",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[28],{"name":29,"class":30},"Shenzhen New Industries Biomedical Engineering Co., Ltd.","UNKNOWN","100553927","correlation-study-of-serum-her-2-against-her-2-adc-drug-efficacy-in-her-2-low-expressing-breast-cancer-100553927",false,"NCT06492447","Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer","Inclusion Criteria:\n\n* 1\\. Subjects with pathologically confirmed breast cancer; 2. The therapeutic drugs are anti-HER2-ADC drugs; 3. No history of other tumors; 4. Age \\> 18 years old; 5. Have relatively complete clinical case characteristics data.\n\nExclusion Criteria:\n\n* 1\\. Male breast cancer subjects; 2. Suffering from other malignant neoplasms; 3. Subjects with incomplete clinical case characteristics.","FEMALE","18 Years",{"count":40,"type":41},50,"ESTIMATED","OBSERVATIONAL","Breast cancer is one of the most common malignancies in women worldwide, with HER2-positive breast cancer accounting for about 15-20% of all breast cancer cases. HER2 (Human epidermal growth factor receptor 2) is a tyrosine kinase receptor that, when overexpressed, promotes the growth and spread of tumor cells. The advent of anti-HER2 therapy, particularly antibody-coupled drugs (ADCs), has resulted in significant survival benefits for HER2-positive breast cancer subjects.\n\nAt present, the value of serum HER2 in the monitoring of anti-HER2-ADC drug therapy is insufficient. The purpose of this study was to investigate changes in serum HER2 expression levels in breast cancer subjects treated with anti-HER2-ADC drugs and the relationship between these changes and treatment effect. The therapeutic effect of HER2 was evaluated by continuous detection of HER2 serum, which provided a theoretical basis for the selection of clinical drug treatment.",[45],"HER 2 Low-expressing Breast Cancer","NOT_YET_RECRUITING","2024-07-02",{"date":49,"type":50},"2024-07-09","ACTUAL",{"date":52,"type":41},"2024-07-04",{"date":54,"type":41},"2026-03-04",{"name":5,"class":6}]